U.S. Stock News

Auna entered this earnings report with a hot stock and a cold reputation on profitability. The shares are up about 24% over the past three months, yet they barely moved after the release, closing at $5.43, only 0.2% above the prior close. That muted reaction contrasts with a healthcare provider reporting Q2 revenue of PEN 1,238.2m and Basic EPS of PEN 0.40, while trailing net profit margin over the past year is only 0.3% with weak interest coverage. Love the revenue scale Auna is putting up...

Armanino Foods of Distinction stock inched up 2.7% to close at US$11.50, a calm reaction for a company that just put another quarter of solid profit on the table. The market appears to be treating this as business as usual. Yet earnings per share of about US$0.16 and a net profit margin near 25% keep reinforcing one story that matters more than the day’s modest move: this is a packaged food company quietly defending rich profitability while trading on a P/E slightly below its industry and...

Amer Sports stock barely flinched after earnings, up about 1% to roughly US$34, even though the quarter landed far from quiet. The company delivered a sharp Q2 revenue jump to US$1.63b and a meaningful lift in net income to US$107.2m. Yet earnings per share eased from Q1 levels, which keeps the focus firmly on how much of that top line is flowing through to the bottom line. Investors came into this print after a softer 30 day share move and a rich P/E multiple. The key question now is whether...

Bruker (BRKR) stock is back in focus after the company expanded its collaboration with Atinary Technologies, pairing Bruker instruments with Atinary’s AI driven Self Driving Lab platforms for automated pharmaceutical and chemical R&D workflows. See our latest analysis for Bruker. The Atinary agreement arrives after a busy few weeks for Bruker, with the stock showing a 30.39% 90 day share price return and a 74.74% total shareholder return over the past year. However, longer term total returns...

Government bond yields have been edging higher as markets react to inflation data and heavier debt issuance, which leaves many growth stocks under pressure. That can create mispricing, especially in fast growing companies where insiders still own meaningful stakes and have clear conviction. This article walks through three stocks from the Fast Growing Stocks With High Insider Ownership screener that fit this profile and explains what makes each one worth a closer look. The three stocks in...

Long term Treasury yields are climbing on fiscal worries, mortgage costs are rising, and housing related stocks are suddenly back in the spotlight. This mix can punish some companies yet open interesting windows for others that are tied to U.S. mortgage and housing finance. This article walks through three stocks exposed to this rate story, explaining how the same macro shock can create very different potential outcomes for your watchlist. The three stocks below are a starting sample. The...

Geron earnings and new RYTELO guidance draw investor focus Geron (GERN) has moved into the spotlight after reporting second quarter and first half 2026 results, along with fresh full year guidance for its oncology drug RYTELO, giving investors clearer visibility on expected revenue. See our latest analysis for Geron. Against this backdrop, Geron’s share price has reacted positively, with a 10.42% 1 month share price return and a 26.19% 3 month share price return building on a 20.45% year to...

The market punished Julong Holding on the day after earnings, with the stock falling 7.3% to ¥7.08, but the headline numbers tell a more nuanced story. The core question for you is whether the profit squeeze that worried traders is as severe as the price move suggests. Julong Holding reported first half 2026 revenue of ¥124.3m and net income of ¥11.7m, which keeps trailing net profit margin at 9.6% compared with 10.8% a year earlier. With the stock still trading on a trailing P/E of 38.9x,...

Hesai Group stock closed up 3.9% at US$17.77 on Wednesday, even though the shares are still down over the past week and past quarter. The market is reacting to one thing above all in this earnings print. Q2 marked a cleanly profitable quarter built on lidar revenue of about RMB 861m and a net margin that now sits in the mid teens over the past year. For short term traders that move looks decisive. For anyone thinking over a multi year horizon, the real story is the profit profile behind that...

Danaher stock has been roughly flat over the past year, while the valuation picture is mixed. A Discounted Cash Flow (DCF) estimate points to a fair price, but broader checks and market multiples suggest the shares are not especially cheap. Over the past 5 years, Danaher has delivered a total return that declined 23.5%, which frames the current valuation debate against a weak longer term share price record. Progress in areas like CRISPR off target analytics and AI enabled digital pathology...

Dow Inc. recently declared a US$0.35 per share dividend, paid on September 11, 2026 to shareholders of record as of August 31, 2026, and entered agreements with Boeing and RTX to support expanded Aegis missile defense system production under the Department of War’s Acquisition Transformation Strategy. This combination of a maintained cash return to shareholders and entry into missile defense manufacturing highlights Dow’s growing role in defense-related supply chains alongside its...

Long term Treasury yields just took a step down after the U.S. Treasury moved to ramp up buybacks, and that small shift in borrowing costs is rippling through equity markets. When cash suddenly looks a bit less comfortable, investors often start hunting for better ways to put short term money to work. This article walks through 3 stocks exposed to that policy news and explains how each might benefit or face new tradeoffs. The three stocks below are just a sample from this theme, and the full...

Tandem Diabetes Care, Inc. reported past second-quarter 2026 results with sales of US$254.56 million and a net loss of US$21.17 million, while reaffirming full-year 2026 sales guidance of about US$1.07 billion to US$1.09 billion. Alongside these results, Tandem’s push into pharmacy-based pump distribution and new insulin delivery technologies suggests a meaningful shift in how it generates and sources its revenue. We’ll now examine how the pharmacy pay-as-you-go shift could reshape Tandem...

Becton, Dickinson and Company recently reported third-quarter fiscal 2026 results showing higher sales of US$4,983,000,000 compared with a year earlier, while net income for both the quarter and year-to-date periods was lower than the prior year. Alongside these mixed earnings, BD advanced its tissue regeneration pipeline by fully enrolling the PREVENT trial for Phasix Mesh and reshaped its quality leadership team with the upcoming appointment of Gary Sorsher as chief quality officer and the...

Atmus Filtration Technologies recently reported second-quarter 2026 results showing sales of US$527.9 million and net income of US$63.9 million, alongside a raised full-year net sales outlook to US$1.975–2.03 billion. The company also increased its quarterly dividend to US$0.06 per share and completed a US$100.98 million buyback, underlining a stronger cash-return profile supported by the integration of its Koch Filter acquisition. Now we will examine how the raised full-year guidance...

In August 2026, Rapport Therapeutics, Inc. reported second-quarter and half-year 2026 results showing a wider net loss, with Q2 net loss at US$56.62 million and basic loss per share from continuing operations at US$1.19, both higher than the prior year period. The six-month net loss rising to US$76.47 million, alongside a higher loss per share of US$1.61, highlights how spending and earnings trends are weighing more heavily on the company’s financial profile. We will assess how this widening...

CoStar Group stock has had a difficult run over the past year, yet the current market price sits at a discount to an intrinsic value estimate based on a Discounted Cash Flow (DCF) model, while broader valuation checks point to a more mixed picture. Over the past 1 year the share price has declined 61.8%, which means recent investors have faced heavy losses even before considering any valuation upside. Recent housing and multifamily data from CoStar platforms such as Homes.com and...

Redwire Corporation recently announced it has signed a teaming agreement with Kanematsu Corporation, making Kanematsu its commercial partner in Japan to support business development across power generation systems, microgravity payloads, and robotics technologies for the country’s growing space industry. This collaboration gives Redwire a local partner to help convert its space technologies into commercial and public-sector opportunities in Japan, potentially broadening its customer base and...

In August 2026, TMC the metals company Inc. reported that its second-quarter net loss narrowed to US$60.12 million, with basic and diluted loss per share from continuing operations improving to US$0.14, while the National Oceanic and Atmospheric Administration issued a Notice of Intent to prepare an Environmental Impact Statement for TMC USA’s USA‑B exploration license application. This Environmental Impact Statement process covers about 122,000 km² of seafloor with an estimated 1.02 billion...

Blackstone stock has delivered a strong 57.4% gain over the past three years, yet the current checks suggest investors are paying a premium to the latest intrinsic value estimate and to traditional valuation multiples. Over the past three years, Blackstone has returned 57.4%, which puts extra focus on whether that share price performance is still supported by fundamentals. Recent activity around AI data center investments and the extended TXNM Energy merger process can influence expectations...

In the past quarter ended July 4, 2026, Ducommun Incorporated reported second-quarter sales of US$224.49 million and net income of US$20.40 million, with diluted earnings per share from continuing operations of US$1.31, all higher than the same period a year earlier. Over the first six months of 2026, Ducommun’s sales of US$433.51 million and net income of US$30.32 million indicate a marked improvement in profitability and earnings per share compared with the prior-year period. With this...

Ionis Pharmaceuticals (NasdaqGS: IONS) and partners Roche and Chugai are advancing RG-6299, an antisense therapy for IgA nephropathy, into a pivotal global Phase III trial. The program targets a major unmet medical need in IgA nephropathy, a chronic kidney disease with limited treatment options. The collaboration structure brings together Ionis' antisense platform with Roche and Chugai's development and commercialization capabilities. Successful Phase III results could support future...

Venture Global stock has delivered a sharp year to date gain while the valuation checks still point to the shares looking inexpensive overall. This raises a clear question about how much of the recent optimism is already reflected in the price. The stock is up 101.7% year to date, which puts recent buyers in a strong position and invites a closer look at whether that pace is sustainable. Progress on large LNG projects and higher export volumes can support higher earnings expectations. At the...

CVS Health (NYSE:CVS) appointed JPMorgan executive Teresa Heitsenrether to its board of directors. The change coincides with the departure of director Larry Robbins. Heitsenrether currently serves as Chief Data & Analytics Officer at JPMorgan, bringing deep experience in data, analytics and artificial intelligence to the CVS Health board. The board change aligns with CVS Health's focus on technology driven healthcare, integrated care and consumer health technology. Readers who want more...